Key Takeaways
- Book-to-bill softens to ~1X: The TTM ratio dipped from 1.2X as order inflow slowed, though management insists capacity is not a constraint and they can serve higher volumes.
- US bioenergy projects face a 2-3 quarter delay: Low-carbon ethanol opportunities remain at the study stage, with finalization timelines shifting right due to a broader US market slowdown.
- CBG and 2G ethanol inch toward commercial proof: The first rice-straw CBG plant began flaring gas and should dispatch by June-end, while IOCL's 2G plant produced first ethanol; both are still stabilizing, so commercial traction is pending.
- New manufacturing capacity and a PLA bet are funded: A ₹200+ crore capex package covers a Praj GenX export-oriented facility near a port, a first-of-its-kind PLA demo plant, and a catalytic lab, all aimed at unlocking future revenue pools.
- What to watch next quarter: Whether the CBG plant begins regular dispatch on schedule, any sign of US project FIDs converting from studies, and the pace of order inflow that determines if the book-to-bill ratio stabilizes.
Order Book & Demand Drivers
- Domestic ethanol orders dominate: The majority of orders came for starchy-feedstock ethanol plants, with sugar mills adding dual-feed capability; the inquiry pipeline signals sustained demand for both starchy and sugary feedstock plants.
- Feedstock mix tilting toward grain: The government is pushing ethanol-drought states toward starchy feedstock, so that share is expected to stay higher, though sugarcane states retain a role as the EBP program extends beyond 20% blending.
- Traditional energy provides ballast: Oil and gas plus fertilizer sectors are driving good traction for CPES solutions, alongside emerging demand for modularized systems tied to green hydrogen, green ammonia, and waste-to-energy.
- Brewery and pharma are back: The brewery and beverage segment has recovered to pre-COVID levels and is expected to convert into capacity expansion orders soon; PHS booked a large pharma fermenter order from Oman and its first semiconductor order for ultra-high-purity water.
- Book-to-bill ratio weakened but capacity is ready: The TTM ratio fell to ~1X from 1.2X; management sidestepped whether it will improve, stating only that capacity is not a bottleneck and they can serve higher book and bill.
Joshipura: "Future is not what we have seen in the past. Future is very different than what we have seen, but it is very exciting. It is very big and therefore we believe that we will be in a position to see a completely different game play out, different segments will emerge."
New Technology Bets: SAF, PLA & CBG
- SAF joint venture with Indian Oil is approved: The board gave in-principle approval for a JV with IOC to produce a variety of biofuels, with SAF likely as the first project; the venture is expected to become functional only toward the end of FY24.
- India's first SAF-powered flight created a policy tailwind: Praj, Air Asia and IOC partnered on a Pune-Delhi commercial flight using indigenously produced SAF; the minister flagged upcoming SAF mandates, and India is a signatory to CORSIA's mandatory blending from 2027.
- PLA demo plant targets a tightly held technology: Only a couple of global companies possess PLA technology and keep it captive; Praj's demo plant at Jejuri aims to bring an independent dimension to the field for food-grade lactic acid and polylactic acid.
- CBG plant is producing gas but not yet dispatching: The first rice-straw-based commercial plant for FCL has commenced biogas generation and flaring; it is under stabilization and should start regular CBG dispatch by end of June 2023, making the next quarter the real proof point.
- Press-mud CBG interest is contingent on demonstrated performance: Management expects more companies to think positively about setting up their own press-mud-to-CBG capacities as the year progresses, but only after the technology's performance is established on the ground.
Joshipura: "We are very confident that our technology will showcase that we are able to produce best in class performance. Having said that we need to wait till the proof of the pudding is there on the ground, which is not too far also."
International Markets: US Slowdown, Europe Conversations
- US low-carbon ethanol projects are delayed, not lost: Activity has slowed due to a broader US market slowdown; projects remain at FEL study stage and the timeline for finalization may shift by 2-3 quarters, with conversion expected when the situation turns.
- Europe pipeline is early-stage and outside the EU: The company is discussing a few potential opportunities for greenfield 1G projects in non-EU European countries, suggesting a cautious, selective approach to that geography.
- Services exports are gaining acceptance: The full suite of enzymes, yeast and performance enhancers is finding high acceptance in both domestic and international markets, supported by a strengthening distributor network.
Capacity Expansion & Capital Allocation
- Praj GenX is the flagship capacity bet: A new subsidiary will operate a modern manufacturing facility near a major port, with commercial production expected by the last quarter of FY24; the ₹100 crore investment could potentially generate 30-40X in sales from that facility over time, per management.
- Capex package also covers R&D infrastructure: The ₹200+ crore board approval includes the PLA demo plant and a new catalytic lab at Praj Matrix, operational by August 2023, aimed at strengthening the technology pipeline.
- Brownfield expansion is the broader model: Similar brownfield approaches are being deployed in other parts of the business to create capacity without proportionate capital intensity.
- JV return expectations are undisclosed: Management declined to comment on expected IRRs or return on capital for the IOC joint venture, calling it "too early" to discuss.
Margins & Mix
- Second-half commodity cooling helped margins: FY23 was a year of two halves: volatile commodity price inflation in H1 gave way to moderation and cooling in H2, which aided margin management alongside a healthier product mix and what management called "tough decisions" to protect margins.
- Volume doubled but revenue did not: Output volume on an equivalent-unit basis doubled from FY22 to FY23, but sales did not keep pace because some projects carry higher bought-out content such as pumps, valves and instrumentation that Praj integrates but does not manufacture.
- Retention money is being managed down: The absolute retention amount has stayed range-bound even as turnover grew, and the company is trying to eliminate retention clauses altogether; retention is linked to mechanical completion and trial run.
- Management will not quantify future margins: When asked how margins would look in FY24 and FY25 assuming stable steel prices, management declined, stating that giving future numbers is not company policy.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| CBG plant regular dispatch | First rice-straw commercial plant to start regular CBG dispatch | End of June 2023 |
| Catalytic lab operational | New lab at Praj Matrix R&D center | August 2023 |
| Praj GenX commercial production | New manufacturing facility near major port to begin commercial production | Last quarter of FY24 |
| IOC joint venture functional | JV with Indian Oil for biofuels production to become functional | End of FY24 |
| US project timeline shift | Low-carbon ethanol project finalization delayed | 2-3 quarters from Q4 FY23 |
| PLA demo plant | First-of-its-kind demo plant for Polylactic Acid at Jejuri | No date given |
Key Metrics
| Metric | Q4 FY23 |
|---|---|
| Consolidated income from operations | ₹1,000 cr, compared to ₹800 cr in Q4 FY22 |
| Profit before tax | ₹100 cr, compared to ₹71.8 cr in Q4 FY22 |
| Profit after tax | ₹88.1 cr, compared to ₹57.6 cr in Q4 FY22 |
| Full-year FY23 income from operations | ₹3,500 cr, compared to ₹2,300 cr in FY22 |
| Full-year FY23 PAT | ₹230 cr, compared to ₹150 cr in FY22 |
| Export revenue share | 17.4% of FY23 total revenue |
| Revenue mix | 73.8% Bioenergy, 19.3% Engineering, 6.9% PHS |
| Order intake | ₹1,000 cr, 76.5% domestic, 82.3% from bioenergy |
| Export order intake | ₹743 cr, 9% YoY growth from ₹679 cr last year |
| Order backlog | ₹3,400 cr, 84.7% domestic, 84% from bioenergy |
| Cash in hand | ₹691 cr as of 31st March 2023 |
| Proposed final dividend | ₹4.50 per equity share, 225% of face value of ₹2 per share |
| Customer advances | ~₹700 cr |
| Receivable days | 83 days, reduced from 86 days in FY22 |
| Output volume growth (equivalent units) | Doubled from FY22 to FY23 |